Sars-Cov-2 Nvx-Cov2373 Vaccine, Recomb (Cvx 313) Dosage

Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.

Usual Adult Dose for COVID-19

FOR INVESTIGATIONAL USE ONLY

No prior history of vaccination: 0.5 mL IM as a series of 2 doses, administered 3 weeks apart
Previously vaccinated with 1 dose of any Novavax vaccine: 0.5 mL IM ONCE to complete the 2-dose series, administered at least 3 weeks after the last dose of Novavax
Previously vaccinated with any COVID-19 vaccine other than Novavax: 0.5 mL IM ONCE, administered at least 2 months after the last dose of COVID-19 vaccine

Comments:

• This drug is not approved by the US FDA to prevent COVID-19. The US FDA has issued an Emergency Use Authorization (EUA) for the use of this drug to prevent COVID-19.
• An additional dose administered at least 2 months following the last dose of this vaccine may be considered for patients who are severely immunocompromised (based on the healthcare provider's discretion).
• No data are available regarding the use of this vaccine to complete a COVID-19 vaccine series initiated with another vaccine.

Use: For active immunization to prevent COVID-19 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Usual Pediatric Dose for COVID-19

For investigational use only

12 years and older:

• No prior history of vaccination: 0.5 mL IM as a series of 2 doses, administered 3 weeks apart
• Previously vaccinated with 1 dose of any Novavax vaccine: 0.5 mL IM ONCE to complete the 2-dose series, administered at least 3 weeks after the last dose of Novavax
• Previously vaccinated with any COVID-19 vaccine other than Novavax: 0.5 mL IM ONCE, administered at least 2 months after the last dose of COVID-19 vaccine

Comments:

• This drug is not approved by the US FDA to prevent COVID-19. The US FDA has issued an EUA for the use of this drug to prevent COVID-19.
• An additional dose administered at least 2 months following the last dose of this vaccine may be considered for patients who are severely immunocompromised (based on the healthcare provider's discretion).
• No data are available regarding the use of this vaccine to complete a COVID-19 vaccine series initiated with another vaccine.

Use: For the emergency use for the active immunization to prevent SARS-CoV-2

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Patients with a known history of severe allergic reaction to the active component or any of the ingredients.
• Patients with a severe allergic reaction (e.g., anaphylaxis) following administration of a COVID-19 vaccine

Safety and efficacy have not been established in patients younger than 12 years.

Dialysis

Data not available

Other Comments

Administration advice:

• For IM administration only. Do not inject IV, intradermally, or subcutaneously.

Storage requirements:

• During storage, minimize exposure to room light and avoid exposure to direct sunlight and ultraviolet light.
• Store refrigerated between 2C and 8C (36F and 46F).
• Do not freeze.
• Consult the manufacturer product information and/or the Fact Sheet for Health Care Providers.

Reconstitution/preparation techniques:

• Prefilled syringes should not be diluted prior to use.
• The manufacturer product information should be consulted.

General:

• This information pertains only to the vaccine product supplied in a vial with a green label stating "Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula)."
• Prefilled syringes contain a single, 0.5 mL dose of vaccine.
• This vaccine does not contain preservatives.

Patient advice:

• To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS): https://vaers.hhs.gov

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer